OPKO Health, Inc. Q3 2025 Earnings Recap

OPK Q3 2025 October 30, 2025

Get alerts when OPK reports next quarter

OPKO Health's Q3 2025 results showcased strategic progress, highlighted by the successful sale of its oncology division and a focus on core clinical operations, driving a commitment to shareholder value.

Earnings Per Share Beat

$0.03 vs $-0.02 est.

+250.0% surprise

Revenue Beat

151669000 vs 139757140 est.

+8.5% surprise

Market Reaction

1-Day +2.1%

5-Day -2.1%

30-Day -7.69%

See OPK alongside your other holdings

Add to your portfolio — free

Key Takeaways

Completed the sale of BioReference Health's oncology division for $192.5 million plus an additional $32.5 million in performance-based earn-out.
Achieved a 5.3% increase in testing volume at BioReference, with a 20% rise in adoption of the 4Kscore test for prostate cancer.
Repurchased $25.1 million in stock during 2025 to enhance shareholder returns, with $126 million remaining under the repurchase program.
Advanced pipeline with four therapeutics in clinical development, including promising candidates in the immuno-oncology space and a COVID-19 antibody initiative.
Focused on operational efficiencies and growth through new customer segments and revenue streams, maintaining a streamlined workforce at BioReference.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit OPK on AllInvestView.